Compare TEX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | KNSA |
|---|---|---|
| Founded | 1933 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 3.4B |
| IPO Year | 1994 | 2018 |
| Metric | TEX | KNSA |
|---|---|---|
| Price | $68.13 | $45.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $66.67 | $55.29 |
| AVG Volume (30 Days) | ★ 2.3M | 515.3K |
| Earning Date | 05-12-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 3.33 | 0.75 |
| Revenue | ★ $5,421,000,000.00 | $677,564,000.00 |
| Revenue This Year | $47.78 | $35.71 |
| Revenue Next Year | $7.13 | $17.13 |
| P/E Ratio | ★ $20.13 | $60.26 |
| Revenue Growth | 5.73 | ★ 60.09 |
| 52 Week Low | $31.53 | $18.26 |
| 52 Week High | $71.50 | $49.12 |
| Indicator | TEX | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 56.88 |
| Support Level | $48.89 | $40.47 |
| Resistance Level | $71.50 | $49.12 |
| Average True Range (ATR) | 2.94 | 2.08 |
| MACD | -0.32 | -0.08 |
| Stochastic Oscillator | 60.89 | 62.25 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.